Wahba, John http://orcid.org/0000-0001-7078-3563
Natoli, Marina http://orcid.org/0000-0002-0270-0225
Whilding, Lynsey M.
Parente-Pereira, Ana C.
Jung, Youngrock
Zona, Stefania
Lam, Eric W.-F. http://orcid.org/0000-0003-1274-3576
Smith, J. Richard
Maher, John http://orcid.org/0000-0001-8275-8488
Ghaem-Maghami, Sadaf http://orcid.org/0000-0002-7369-5080
Funding for this research was provided by:
Imperial Experimental Cancer Medicine Centre
Cancer Research UK Imperial Centre
Imperial NIHR Biomedical Research Centre
Article History
Received: 19 January 2018
Accepted: 4 July 2018
First Online: 24 August 2018
Compliance with ethical standards
:
: John Maher is chief scientific officer and a co-founder of Leucid Bio which seeks to commercialize CAR T-cell immunotherapeutic approaches. All other authors declare that they have no conflict of interest.
: Ethical approval for the collection of blood samples from healthy volunteers was granted by West London Research Ethics Committee (Reference 10/H0707/7). All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. In particular, all in vivo experimentation adhered to current United Kingdom Home Office guidelines, as specified in project license 70/7997, and was approved by Imperial College’s Animal Welfare and Ethical Review Body (AWERB).
: Written consent was obtained from all volunteers who provided blood samples for this work.
: All animals were purchased from Charles Rivers Laboratories, Burlington, USA.
: SKOV-3-luc and OVCAR-4 cell lines were authenticated by Eurofins Genomics (Ebersberg, Germany).